Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel

Abstract

Daphné Denis,1 Nathalie Beneton,1 Kamel Laribi,2 Hervé Maillard1 1Dermatology Department, Centre Hospitalier Le Mans, Le Mans, France; 2Haematology Department, Centre Hospitalier Le Mans, Le Mans, France Abstract: Mycosis fungoides (MF) is a low-grade cutaneous lymphoma accounting for more than half of primary cutaneous T-cell lymphomas (CTCLs). Due to the rarity of CTCL, randomized studies are lacking, and treatment is based mainly on the recent published European Organisation for Research and Treatment of Cancer guidelines. Basically, early-stage MF is treated with skin-directed treatments, whereas advanced-stage MF requires more aggressive therapies. Among the skin-directed therapies, nitrogen mustard has been used for more than 50 years. A gel formulation was developed recently, showing a slight decrease in efficacy, counterbalanced by better tolerance (essentially due to a decrease in delayed hypersensitivity reactions). This review aims to summarize the current management of MF and the role of chlormethine gel in the treatment of the disease. Keywords: mycosis fungoides, nitrogen mustard, mechlorethamine, chlormethine, gel  

Keywords

• mycosis fungoides
• nitrogen mustard
• mechlorethamine
• chlormethine
• gel